1. Home
  2. FXNC vs SABS Comparison

FXNC vs SABS Comparison

Compare FXNC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First National Corporation

FXNC

First National Corporation

N/A

Current Price

$28.75

Market Cap

258.1M

Sector

Finance

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$2.85

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FXNC
SABS
Founded
1907
2014
Country
United States
United States
Employees
308
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
258.1M
293.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
FXNC
SABS
Price
$28.75
$2.85
Analyst Decision
Hold
Strong Buy
Analyst Count
3
11
Target Price
★ $33.00
$11.64
AVG Volume (30 Days)
12.7K
★ 684.9K
Earning Date
10-23-2026
11-05-2026
Dividend Yield
★ 2.63%
N/A
EPS Growth
★ 96.00
78.53
EPS
★ 1.93
N/A
Revenue
★ $7,717,000.00
N/A
Revenue This Year
$7.52
N/A
Revenue Next Year
$4.62
N/A
P/E Ratio
$15.02
★ N/A
Revenue Growth
★ 7.40
N/A
52 Week Low
$23.71
$2.44
52 Week High
$33.24
$5.15

Technical Indicators

Market Signals
Indicator
FXNC
SABS
Relative Strength Index (RSI) 37.27 43.62
Support Level $28.80 $2.44
Resistance Level $30.57 $4.03
Average True Range (ATR) 0.89 0.26
MACD -0.19 -0.02
Stochastic Oscillator 16.91 37.58

Price Performance

Historical Comparison
FXNC
SABS

About FXNC First National Corporation

First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: